You are here

News

05/20/2021

Our new database of in vivo gene therapy clinical trials is comparable in data quality to a scholarly publication, but it is curated through a more recent endpoint and the database can be downloaded. Other databases of gene therapy trials usually combine in vivo therapy together wth ex vivo therapy. Some existing databases are automatically generated by software and contain many false poitives; consequently the statistics based on that automatic data are incorrect.

Read more...
04/25/2021

Between 2019 and 2020, the number of new clinical trials in advanced cell therapy increased by 29%. All categories of trials increased, but the most dramatic rise was a near doubling of trials that employ MSC. COVID-19 trials accounted for about 80% of the increased number of MSC clinical trials.

Read more...
10/24/2020

As of August 2020, there are 230 companies worldwide developing CAR-immunotherapy, and 80 (35%) of those companies have allogeneic products in their pipeline. These allogeneic CAR products are spread across 15 nations, with 48% in the United States and 83% outside of China.

Read more...
10/10/2020

A simple search for keywords leaves the impression that there are hundreds of exosome clinical trials. But once we apply the requirements that the product meets the ISEV definition and has a clearly defined purification step, there are less than one hundred exosome clinical trials worldwide to date.

Read more...
09/13/2020

We have published the first look at how the cytokine response to COVID-19 overlaps with the leading cytokines seen in Graft versus Host Disease (GvHD). Cytokine markers have proven predictive for disease severity and outcome during inflammatory disorders. Hence, the fact that MSC have proven effective at treating GvHD bodes well for MSC therapies of COVID-19.

Read more...
08/29/2020

CellTrials.org has launched the world's first database of exosome clinical trials and their publications. Although we use the popularized term exosomes, in fact we include all clinical trials that employ any form of Extracellular Vesicles (EV) and/or Conditioned Medium (CdM).

Read more...
08/04/2020

COVID-19 is a moving target for clinical trials: as the outbreaks move, either from one country to another or within a country, clinical trial managers must partner with different hospitals to recruit patients. Only those trial sponsors that are strong enough to form relationships with multiple hospitals will be able to accrue large numbers of patients for their trials.

Read more...
05/25/2020

CellTrials.org suggests that pulmonary fibrosis in COVID-19 survivors is a new opportunity for MSC therapy, and may be the most feasible and effective application of MSC to Coronavirus.

Read more...
05/11/2020

Despite COVID-19, nearly 30% more advanced cell therapy trials were registered during 2020 Q1 than in the previous year. The fraction of the non-COVID-19 trials that are recruiting is about the same as last year.

Read more...
04/29/2020

We present a table that compares media coverage in the western hemisphere versus clinical trial registration for cell therapy companies that propose to treat some aspect of COVID-19. During this time of upheaval, some companies are bypassing the normal trial registration process and entering clinical applications based on Compassionate Use Exemptions or  Emergency Use Authorizations.

Read more...